市场调查报告书
商品编码
1541802
2024-2032 年按产品(免疫抑制剂、免疫刺激剂)、应用(肿瘤、呼吸、HIV 等)和地区分類的免疫调节剂市场报告Immunomodulators Market Report by Product (Immunosuppressants, Immunostimulants), Application (Oncology, Respiratory, HIV, and Others), and Region 2024-2032 |
2023年全球免疫调节剂市场规模达2,112亿IMARC Group。
免疫调节剂是一组用于改变针对传染病、免疫缺陷和抗体转移改变的免疫反应的药物。这些药物通常包括单株抗体、细胞激素、左旋咪唑和卡介苗(BCG)。它们广泛用于治疗癌症、气喘、肿瘤、遗传性血管性水肿和自体免疫疾病,如天疱疮、红斑性狼疮、过敏和类风湿关节炎。如今,一些医疗保健提供者推荐免疫调节剂与其他药物(例如生物製剂)一起用于治疗发炎性肠道疾病(IBD)。
由于快速城市化、收入水平上涨以及加工食品消费的增加,个人不健康的生活方式导致全球慢性病盛行率显着上升。这进一步增加了对器官移植的需求,这对作为器官移植受者有前途的治疗剂的局部免疫调节剂的需求产生了积极影响。此外,人口老化的加剧和事故数量的增加也增加了器官衰竭的风险。因此,一些管理和非管理当局正在鼓励器官捐赠,这反过来又促进了全球局部免疫调节剂的销售。除此之外,发炎性肠道疾病和自体免疫疾病的盛行率不断上升也推动了市场的成长。免疫调节剂也用于联合治疗,以减少对类固醇的长期需求,防止復发,并治疗对抗生素无反应的疾病。此外,包括氟伏沙明、托珠单抗和巴瑞替尼合併瑞德西韦在内的多种免疫调节剂正在用于治疗冠状病毒病 (COVID-19) 住院患者。除此之外,一些候选产品目前正处于后期临床试验阶段。这些产品的开发预计将扩大免疫调节剂在治疗各种危及生命的疾病方面的应用。
The global immunomodulators market size reached US$ 211.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 331.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032.
Immunomodulators are a group of drugs used to modify an immune response against infectious diseases, immunodeficiency, and alterations in antibody transfer. These drugs generally include monoclonal antibodies, cytokines, levamisole, and Bacillus Calmette-Guerin (BCG). They are widely used to treat cancer, asthma, tumors, hereditary angioedema, and autoimmune disorders like pemphigus, lupus, allergies, and rheumatoid arthritis. Nowadays, several healthcare providers are recommending immunomodulators with other agents, such as biologics, for managing inflammatory bowel disease (IBD).
The unhealthy lifestyles of individuals on account of rapid urbanization, inflating income levels, and the increasing consumption of processed food products has led to a significant rise in the prevalence of chronic diseases worldwide. This is further escalating the need for organ transplantation, which is positively influencing the demand for topical immunomodulators as a promising therapeutic agent in organ transplant recipients. Moreover, the rising aging population and the growing number of accidents are also increasing the risk of organ failure. Consequently, several governing and non-governing authorities are encouraging organ donation, which, in turn, is boosting the sales of topical immunomodulators worldwide. Apart from this, the increasing prevalence of IBD and autoimmune disorders is bolstering the market growth. Immunomodulators are also utilized in combination therapy to decrease the long-term need for steroids and prevent recurring flares and treat diseases that do not respond to antibiotics. Furthermore, several immunomodulators, including Fluvoxamine, Tocilizumab, and Baricitinib with Remdesivir, are finding application for treating hospitalized patients with coronavirus disease (COVID-19). Besides this, several product candidates are currently in late-stage clinical trials. The development of these products is anticipated to expand the applications of immunomodulators for treating various life-threatening diseases.
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunomodulators market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and application.
Immunosuppressants
Antibodies
Calcineurin Inhibitors
Glucocorticoids
Antimetabolites
Others
Immunostimulants
Vaccines
Antibodies
Others
Oncology
Respiratory
HIV
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG and Pfizer Inc.